LLY

754.8

+2.95%↑

JNJ

154.98

+0.66%↑

UNH

379.64

-0.19%↓

ABBV

191.89

+4.15%↑

ABT

133.55

+0.22%↑

LLY

754.8

+2.95%↑

JNJ

154.98

+0.66%↑

UNH

379.64

-0.19%↓

ABBV

191.89

+4.15%↑

ABT

133.55

+0.22%↑

LLY

754.8

+2.95%↑

JNJ

154.98

+0.66%↑

UNH

379.64

-0.19%↓

ABBV

191.89

+4.15%↑

ABT

133.55

+0.22%↑

LLY

754.8

+2.95%↑

JNJ

154.98

+0.66%↑

UNH

379.64

-0.19%↓

ABBV

191.89

+4.15%↑

ABT

133.55

+0.22%↑

LLY

754.8

+2.95%↑

JNJ

154.98

+0.66%↑

UNH

379.64

-0.19%↓

ABBV

191.89

+4.15%↑

ABT

133.55

+0.22%↑

Search

Heron Therapeutics Inc

Avatud

SektorTervishoid

2.09 -0.48

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

2.09

Max

2.18

Põhinäitajad

By Trading Economics

Sissetulek

8.5M

3.7M

Müük

-1.5M

41M

Aktsiakasum

0.02

Kasumimarginaal

8.982

Töötajad

122

EBITDA

13M

8.7M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+200% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

5. aug 2025

Turustatistika

By TradingEconomics

Turukapital

83M

352M

Eelmine avamishind

2.57

Eelmine sulgemishind

2.09

Uudiste sentiment

By Acuity

25%

75%

48 / 382 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Bearish Evidence

Heron Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

11. mai 2025, 23:48 UTC

Tulu
Omandamised, ülevõtmised, äriostud

Dyno Nobel Returns to 1st Half Profit; Strikes Fertilizers Deals -- Update

11. mai 2025, 23:46 UTC

Market Talk

Nikkei May Rise on Hopes for U.S.-China Trade Talks -- Market Talk

11. mai 2025, 23:45 UTC

Market Talk

Oil Rises Amid Improved Market Mood -- Market Talk

11. mai 2025, 23:38 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Aristocrat Has Significant Firepower for M&A -- Market Talk

11. mai 2025, 23:36 UTC

Market Talk

Global Markets Uncertain About US-China Trade News -- Market Talk

11. mai 2025, 23:35 UTC

Market Talk

Gold Falls, Dragged by Weakening Safe-Haven Demand, Possible Profit-Taking -- Market Talk

11. mai 2025, 23:33 UTC

Tulu
Omandamised, ülevõtmised, äriostud

Dyno Nobel Returns to 1H Profit; Strikes Fertilizers Deals -- Update

11. mai 2025, 23:32 UTC

Peamised uudised

Proposal Cutting Medicaid Aims for GOP Middle Ground -- WSJ

11. mai 2025, 22:44 UTC

Market Talk

Centaurus Metals's Jaguar Project Faces Funding Hurdles -- Market Talk

11. mai 2025, 22:33 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Domain Takeover Could Create Near-Term Overhang on REA Stock -- Market Talk

11. mai 2025, 20:19 UTC

Peamised uudised

Bessent Says U.S.-China Trade Talks Were 'Productive,' Without Offering Specifics -- WSJ

11. mai 2025, 16:00 UTC

Peamised uudised

Trump's Budget Hawk Takes Over the DOGE Agenda. First Up: the Military -- WSJ

11. mai 2025, 11:00 UTC

Peamised uudised

This Obscure New York Court Is Set to Decide Fate of Trump's Tariffs -- WSJ

11. mai 2025, 08:00 UTC

Peamised uudised

China's Property Market Is a Tale of Big Cities. Everywhere Else Is Struggling. -- Barrons.com

11. mai 2025, 01:00 UTC

Peamised uudised

The Spring Home Sales Season Is Shaping Up to Be a Dud -- WSJ

11. mai 2025, 01:00 UTC

Peamised uudised

Europe Threatens Nord Stream 2 Sanctions to Pressure Russia on Cease-Fire -- WSJ

10. mai 2025, 21:54 UTC

Peamised uudised

GOP Tax Bill Seeks to Put Cash in Taxpayers' Pockets in Early 2026 -- Update

10. mai 2025, 17:12 UTC

Peamised uudised

Europe Threatens Nord Stream 2 Sanctions to Pressure Russia to Cease Fire -- WSJ

10. mai 2025, 15:41 UTC

Peamised uudised

Fed Officials Signal Pause on Adjusting Interest Rates as Trade Risks Mount -- Barrons.com

10. mai 2025, 12:00 UTC

Peamised uudised

Why a Sorority Is Taking on Trump's Budget Cuts -- WSJ

10. mai 2025, 09:30 UTC

Peamised uudised

The Giants of Silicon Valley Are Having a Midlife Crisis Over AI -- WSJ

10. mai 2025, 08:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

10. mai 2025, 03:52 UTC

Peamised uudised

China Struggles With Persistent Disinflationary Pressures as Tariffs Bite -- WSJ

9. mai 2025, 23:51 UTC

Omandamised, ülevõtmised, äriostud

Oil at $50? The High Cost of Cheap Crude. -- Barrons.com

9. mai 2025, 22:06 UTC

Market Talk

Arm Holdings Remains a Strong Growth Story -- Market Talk

9. mai 2025, 21:37 UTC

Peamised uudised

U.S. Sets August Deadline for Debt Ceiling -- WSJ

9. mai 2025, 21:10 UTC

Peamised uudised

The Score: Disney, Berkshire Hathaway, Ford and More Stocks That Defined the Week -- WSJ

9. mai 2025, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

9. mai 2025, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

9. mai 2025, 20:42 UTC

Peamised uudised

Stocks Get a Break From Trade Chaos -- WSJ

Võrdlus sarnastega

Hinnamuutus

Heron Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

200% tõus

12 kuu keskmine prognoos

Keskmine 6.33 USD  200%

Kõrge 9 USD

Madal 4 USD

Põhineb 3 Wall Streeti analüütiku instrumendi Heron Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

3 ratings

3

Osta

0

Hoia

0

Müü

Tehniline skoor

By Trading Central

2.0001 / 2.42Toetus ja vastupanu

Lühikene perspektiiv

Bearish Evidence

Keskpikk perspektiiv

Bullish Evidence

Pikk perspektiiv

Bullish Evidence

Sentiment

By Acuity

48 / 382 Pingereas Tervishoid

Uudiste sentiment

Väga tugevad tõusu märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Üle keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Heron Therapeutics Inc

Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in Cary, North Carolina.